Company news
Journey Medical Corporation news in 2024
Journey Medical Corporation's news releases, calls and decks from 2024, newest first.
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 11, 2024
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
November 3, 2024
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
October 24, 2024
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 2, 2024
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
September 8, 2024
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 11, 2024
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
August 5, 2024
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
July 16, 2024
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
July 10, 2024
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 14, 2024
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 12, 2024
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
May 6, 2024
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
April 30, 2024
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
April 24, 2024
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 20, 2024
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
March 17, 2024
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
March 14, 2024
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
March 12, 2024
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
March 10, 2024
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
January 4, 2024
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
January 1, 2024